uracil has been researched along with Hypertension in 18 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "0 g/kg food) provided significant protection against elevation of blood pressure and cardiac hypertrophy in male rats treated with desoxycorticosterone trimethylacetate (DTMA) (5." | 7.65 | Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats. ( Fregly, MJ; Rubin, ML, 1977) |
| "Urapidil was found effective in the treatment of hypertension during extracorporeal circulation." | 6.65 | Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. ( Barankay, A; Göb, E; Richter, JA, 1981) |
| "0 g/kg food) provided significant protection against elevation of blood pressure and cardiac hypertrophy in male rats treated with desoxycorticosterone trimethylacetate (DTMA) (5." | 3.65 | Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats. ( Fregly, MJ; Rubin, ML, 1977) |
| "Conclusions In patients with type 2 diabetes mellitus and recent acute coronary syndrome, average BP s <130/80 mm Hg were associated with worsened cardiovascular outcomes." | 2.87 | Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. ( Bakris, GL; Bergenstal, R; Cannon, CP; Cushman, WC; Heller, SR; Jalil, F; Liu, Y; Mehta, C; White, WB; Zannad, F, 2018) |
| "Urapidil was found effective in the treatment of hypertension during extracorporeal circulation." | 2.65 | Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine. ( Barankay, A; Göb, E; Richter, JA, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Wiegand, J | 1 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 1 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 1 |
| Manns, MP | 1 |
| Zeuzem, S | 1 |
| Berg, T | 1 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Fan, SH | 1 |
| Xiong, QF | 1 |
| Wang, L | 1 |
| Zhang, LH | 1 |
| Shi, YW | 1 |
| Wang, J | 1 |
| Fan, S | 1 |
| Xiong, Q | 1 |
| Niu, Y | 1 |
| Zhang, X | 1 |
| Qin, J | 1 |
| Shi, Y | 1 |
| Zhang, L | 1 |
| White, WB | 1 |
| Jalil, F | 1 |
| Cushman, WC | 1 |
| Bakris, GL | 1 |
| Bergenstal, R | 1 |
| Heller, SR | 1 |
| Liu, Y | 1 |
| Mehta, C | 1 |
| Zannad, F | 1 |
| Cannon, CP | 1 |
| Kishimoto, S | 1 |
| Kinoshita, Y | 1 |
| Matsumoto, T | 1 |
| Maruhashi, T | 1 |
| Kajikawa, M | 1 |
| Matsui, S | 1 |
| Hashimoto, H | 1 |
| Takaeko, Y | 1 |
| Kihara, Y | 1 |
| Chayama, K | 1 |
| Goto, C | 1 |
| Mohamad Yusoff, F | 1 |
| Nakashima, A | 1 |
| Noma, K | 1 |
| Higashi, Y | 1 |
| Liu, YY | 1 |
| Zeng, SY | 1 |
| Leu, YL | 1 |
| Tsai, TY | 1 |
| Nishimura, A | 1 |
| Nishida, M | 1 |
| CANELLAKIS, ES | 1 |
| Barankay, A | 2 |
| Göb, E | 2 |
| Richter, JA | 2 |
| Fischer, R | 1 |
| Haerlin, R | 1 |
| Steinijans, V | 2 |
| Zech, K | 1 |
| Bruckschen, EG | 2 |
| Sumi, S | 1 |
| Kidouchi, K | 1 |
| Hayashi, K | 1 |
| Imaeda, M | 1 |
| Asai, M | 1 |
| Wada, Y | 1 |
| Fregly, MJ | 1 |
| Rubin, ML | 1 |
| Henze, F | 1 |
| Michael, G | 1 |
| Schoetensack, W | 1 |
| Bischler, P | 1 |
| Dittmann, EC | 1 |
| Salvati, P | 1 |
| Vaghi, F | 1 |
| Colombo, M | 1 |
| Bianchi, G | 1 |
| Hueber, EF | 1 |
| Stupnitskiĭ, AA | 1 |
| Golikov, BM | 1 |
| Apanasenko, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
1 review available for uracil and Hypertension
| Article | Year |
|---|---|
Purinergic signaling in cardiovascular system.
Topics: Adenosine; Animals; Cardiovascular System; Humans; Hypertension; Risk Factors; Signal Transduction; | 2017 |
3 trials available for uracil and Hypertension
| Article | Year |
|---|---|
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.
Topics: Aged; Analysis of Variance; Blood Pressure Determination; Cause of Death; Diabetes Mellitus, Type 2; | 2018 |
Control of hypertension during cardiopulmonary bypass with urapidil and phentolamine.
Topics: Aged; Anesthesia; Antihypertensive Agents; Cardiopulmonary Bypass; Hemodynamics; Humans; Hypertensio | 1981 |
[Clinical trials of urapidil. Review of human pharmacological studies with a summary of a multi-center study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Electrophysiology; Femal | 1978 |
14 other studies available for uracil and Hypertension
| Article | Year |
|---|---|
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway.
Topics: Animals; Blood Pressure; Cells, Cultured; Dipeptidyl-Peptidase IV Inhibitors; Down-Regulation; Gene | 2020 |
Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways.
Topics: Adenylate Kinase; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Cardiome | 2021 |
Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Arterial Pressure; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2019 |
Antihypertensive Effect of a Combination of Uracil and Glycerol Derived from Lactobacillus plantarum Strain TWK10-Fermented Soy Milk.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Antioxidants; Drug Thera | 2015 |
Pyrimidine metabolism. III. The interaction of the catabolic and anabolic pathways of uracil metabolism.
Topics: Hypertension; RNA; Uracil | 1957 |
Treatment of hypertension in coronary bypass surgery. Clinical experience with urapidil.
Topics: Adult; Aged; Coronary Artery Bypass; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hyperte | 1981 |
Preliminary results on the correlation between serum level and antihypertensive effect of urapidil (Ebrantil).
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension; Male; Piperazines; Time Factors; Uraci | 1981 |
Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio.
Topics: Adult; Cerebral Infarction; Dihydrouracil Dehydrogenase (NADP); Female; Humans; Hypertension; Liver | 1998 |
Effect of some substituted pyrimidines on development of desoxycorticosterone-induced hypertension in rats.
Topics: Animals; Body Weight; Cardiomegaly; Desoxycorticosterone; Hematocrit; Hemoglobins; Hypertension; Mal | 1977 |
[Studies on the influence of the antihypertensive drug urapidil on blood circulation and its regulation in animal experiments (author's transl)].
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Carotid Sinus; Cats; Dogs; Efferen | 1977 |
A new selective antagonist of vascular serotonin receptors lowers blood pressure in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Ergolines; Hypertension; In Vitro Techniq | 1988 |
[Treatment of arterial hypertension with new drugs. 2. Moderate arterial hypertension: 4-aminouracil-phenylpiperazine].
Topics: Humans; Hypertension; Piperazines; Uracil | 1972 |
[Mechanism of changes in the duration of the phase of asynchronous contraction in patients with hypertensive disease and atherosclerosis].
Topics: Adult; Aged; Antihypertensive Agents; Coronary Disease; Female; Guanethidine; Heart; Humans; Hyperte | 1971 |